Get the Stockscreener App
7.7552
2.65%
0.2152
CorMedix Inc stock is traded at $7.7552, with a volume of 1.70M.
It is up +2.65% in the last 24 hours and down -8.08% over the past month.
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
See More
Previous Close:
$7.54
Open:
$7.55
24h Volume:
1.70M
Relative Volume:
1.23
Market Cap:
$604.85M
Revenue:
$400.05M
Net Income/Loss:
$181.01M
P/E Ratio:
3.6942
EPS:
2.0993
Net Cash Flow:
$194.58M
1W Performance:
+2.78%
1M Performance:
-8.08%
6M Performance:
+7.35%
1Y Performance:
-40.14%
1-Day Range:
$7.4801
$8.11
1-Week Range:
$7.10
$8.98
52-Week Range:
$6.125
$14.96
CorMedix Inc Stock (CRMD) Company Profile
Name
CorMedix Inc
Sector
Industry
Phone
908-517-9500
Address
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
7.76 | 587.70M | 400.05M | 181.01M | 194.58M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
515.82 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.91 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.85 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.63 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.19 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | D. Boral Capital | Hold → Buy |
| Jun-30-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Leerink Partners | Outperform |
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Aug-26-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-17-21 | Initiated | Needham | Buy |
| Sep-29-20 | Initiated | JMP Securities | Mkt Outperform |
| Sep-21-20 | Initiated | Truist | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Mar-26-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-06-18 | Initiated | ROTH Capital | Buy |
| Sep-25-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-17 | Reiterated | Rodman & Renshaw | Buy |
| May-05-17 | Reiterated | Rodman & Renshaw | Buy |
| Nov-11-16 | Reiterated | FBR & Co. | Outperform |
| Mar-17-16 | Reiterated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | FBR Capital | Outperform |
| Nov-16-15 | Reiterated | ROTH Capital | Neutral |
| Oct-29-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-08-14 | Reiterated | ROTH Capital | Buy |
| Oct-03-11 | Downgrade | Maxim Group | Buy → Hold |
View All
CorMedix Inc Stock (CRMD) Latest News
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade - marketbeat.com
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright - marketbeat.com
(CRMD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
CorMedix Inc (CRMD) Stock News Today - TradingKey
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CorMedix Stock Jumps on Strong DefenCath Sales - Sahm
Full Transcript: Cormedix Q2 2026 Earnings Call - Sahm
CorMedix (NASDAQ:CRMD) Shares Down 4.6%Here's Why - marketbeat.com
Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price - marketbeat.com
CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says - marketscreener.com
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains - The Globe and Mail
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating - Moomoo
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
H.C. Wainwright reiterates CorMedix stock rating on strong quarter By Investing.com - Investing.com India
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CorMedix (CRMD) Q2 2026 Earnings Call: Revenue Hits $101.9M, EBITDA Guidance Raised - TradingKey
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages - marketbeat.com
CorMedix Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CorMedix Shares Surge 17% as Q2 Revenue Tops $100 Million, EBITDA Outlook Raised - finance.biggo.com
CorMedix Q2 2026 Earnings Call Transcript - MarketBeat
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix Inc (NASDAQ: CRMD) Share Price, CRMD Stock News, CRMD Share Price & Updates - kalkine.ca
CorMedix Shares Rise After Q2 Results, Guidance - marketscreener.com
CorMedix (NASDAQ:CRMD) Releases Earnings Results, Beats Estimates By $0.05 EPS - marketbeat.com
CorMedix Q2 revenue hits $101.9M; DEFSEC up 92% YoY - scanx.trade
CorMedix Q2 Earnings Call Highlights - MarketBeat
CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
CorMedix CEO Expects Supplemental Filing For Fungal Disease Treatment By Q3 – CRMD Stock Sees Best Day In Nearly 10 Months After Earnings Beat - Yahoo Finance
CorMedix earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Earnings call transcript: CorMedix tops Q2 2026 estimates, shares jump 16% - Investing.com Australia
CorMedix (NASDAQ:CRMD) Shares Gap Up Following Earnings Beat - marketbeat.com
CorMedix Announces Q2 2026 Revenue Surge to $101.9 Million and Strong Net Income - Kalkine Media
Accelerant Holdings, CorMedix, Birkenstock And Other Big Stocks Moving Higher On Thursday - benzinga.com
CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline advances driving raised guidance - TradingView
CorMedix Inc. Reiterates Consolidated Earnings Guidance for the Year 2026 - marketscreener.com
Why is CorMedix stock surging today? By Investing.com - Investing.com South Africa
Transcript : CorMedix Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
CorMedix Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CRMD: Q2 revenue and EBITDA soared, with new supply deals and pipeline progress driving raised guidance - TradingView
Why is CorMedix stock surging today? - Investing.com
CorMedix Inc. (CRMD) Stock Price, News, Quote & History - Yahoo! Finance Canada
CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates - Yahoo Finance UK
Form 8K CorMedix Inc For: 13 August By Investing.com - Investing.com Australia
CorMedix Inc. (CRMD) revenue jumps as Melinta deal boosts Q2 2026 profit - Stock Titan
CRMD: Q2 2026 revenue and earnings rose sharply, driven by DefenCath and Melinta portfolio growth - TradingView
CorMedix: Q2 Earnings Snapshot - AOL.com
CorMedix reports Q2 2026 consolidated revenue $101.9M, net income $26.0M, adjusted EBITDA $58.7M - TradingView
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
CorMedix (CRMD) Earnings Date and Reports 2026 - MarketBeat
CorMedix Inc $CRMD Shares Purchased by Hennion & Walsh Asset Management Inc. - marketbeat.com
Cormedix Wins Preliminary OK on Governance Settlement Reforms - The Globe and Mail
CorMedix Inc Stock (CRMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):